Revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Karyopharm Therapeutics Inc. (KPTI)
Price$0.8022Cached quote
Net income
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $146.1M | $145.2M | $146.0M | $157.1M | $209.8M | $108.1M | $40.9M | $30.3M | $1.6M | $154,000 | $250,000 | $229,000 | $387,000 | $634,000 | $152,000 | — | — |
| Research & development | $125.6M | $143.2M | $138.8M | $148.7M | $160.8M | $150.8M | $122.3M | $161.4M | $107.3M | $86.9M | $97.7M | $60.1M | $28.5M | $14.1M | $8.6M | — | — |
| Operating expenses | $236.8M | $264.7M | $275.6M | $299.3M | $308.1M | $279.9M | $230.2M | $210.2M | $132.1M | $110.9M | $119.3M | $76.1M | $34.3M | $16.5M | $10.5M | — | — |
| Operating income | −$90.7M | −$119.4M | −$129.5M | −$142.2M | −$98.3M | −$171.8M | −$189.3M | −$179.9M | −$130.5M | −$110.7M | −$119.1M | −$75.8M | −$34.0M | −$15.9M | −$10.3M | — | — |
| Operating margin | −62.10% | −82.24% | −88.71% | −90.53% | −46.84% | −159.00% | −462.85% | −592.97% | −8,133.21% | −71,903.90% | −47,630.40% | −33,120.52% | −8,772.61% | −2,506.31% | −6,783.55% | — | — |
| EBITDA | −$90.4M | −$119.1M | −$129.0M | −$141.6M | −$97.5M | −$170.9M | −$188.3M | −$179.1M | −$129.8M | −$110.0M | −$118.4M | −$75.5M | −$33.8M | −$15.8M | −$10.2M | — | — |
| EBITDA margin | −61.90% | −82.01% | −88.34% | −90.14% | −46.46% | −158.10% | −460.47% | −590.55% | −8,088.79% | −71,438.31% | −47,376.80% | −32,979.48% | −8,735.40% | −2,487.07% | −6,728.95% | — | — |
| Net income | −$196.0M | −$76.4M | −$143.1M | −$165.3M | −$124.1M | −$196.3M | −$199.6M | −$178.4M | −$129.0M | −$109.6M | −$118.2M | −$75.8M | −$33.9M | −$15.9M | — | — | — |
| Net profit margin | −134.21% | −52.62% | −97.99% | −105.23% | −59.14% | −181.59% | −488.08% | −588.10% | −8,036.39% | −71,153.90% | −47,272.40% | −33,090.39% | −8,771.83% | −2,505.99% | — | — | — |
| Basic EPSper basic share | -$17.93 | -$9.41 | -$18.79 | -$30.30 | -$24.75 | -$40.80 | -$48.30 | -$47.10 | -$42.15 | -$43.80 | -$49.80 | -$36.45 | -$83.85 | -$134.25 | -$154.05 | — | — |
| Diluted EPSper diluted share | -$17.93 | -$14.00 | -$18.79 | -$30.30 | -$24.75 | -$40.80 | -$48.30 | -$47.10 | -$42.15 | -$43.80 | -$49.80 | -$36.45 | -$83.85 | -$134.25 | -$154.05 | — | — |
Owners
Reported shareholders
8.45%of listed shares
RA CAPITAL MANAGEMENT, L.P.1.92M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
RA CAPITAL MANAGEMENT, L.P. | 8.45%1.92M shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 6.71%1.52M shares |
ACORN CAPITAL ADVISORS, LLC | 6.69%1.52M shares |
GOLDMAN SACHS GROUP INC | 6.28%1.42M shares |
BlackRock, Inc. | 6.26%1.42M shares |
Kalehua Capital Management LLC | 6.05%1.37M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.23%958.98K shares |
Catalio Capital Management, LP | 4.15%940.86K shares |
Avidity Partners Management LP | 4.08%924.49K shares |
T. Rowe Price Investment Management, Inc. | 3.47%786.31K shares |
TWO SIGMA INVESTMENTS, LP | 3.07%695.26K shares |
NEA Management Company, LLC | 2.54%576.78K shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.34%531.23K shares |
Ghisallo Capital Management LLC | 2.20%500K shares |
Soleus Capital Management, L.P. | 1.94%440K shares |
Mason Michael | ≈1.72%391.05K shares |
UBS Group AG | 1.56%353.55K shares |
STATE STREET CORP | 1.44%325.99K shares |
Affinity Asset Advisors, LLC | 1.38%312.5K shares |
Brevan Howard Capital Management LP | 1.37%309.82K shares |
Percentages use 22.68M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 14, 2026Form 4 | Poulton StuartEVP, Chief Development Officer | SellCommon Stock | 403 | $9.50 | $3.8K | 94.8K |
| May 14, 2026Form 4 | Rangwala ReshmaEVP & Chief Medical Officer | SellCommon Stock | 408 | $9.50 | $3.9K | 56.8K |
| May 14, 2026Form 4 | Cheng Sohanya RoshanEVP & Chief Commercial Officer | SellCommon Stock | 324 | $9.50 | $3.1K | 107.9K |
| May 14, 2026Form 4 | Abate KristinChief Accounting Officer | SellCommon Stock | 53 | $9.50 | $503.50 | 23.8K |
| May 14, 2026Form 4 | Paulson Richard A.President and CEO | SellCommon Stock | 2.2K | $9.50 | $20.9K | 269.7K |